NCT06580106View on ClinicalTrials.gov

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

January 31, 2030

Conditions
Leukemia, Myeloid, Acute
Interventions
OTHER

Biospecimen samples

Buccal swabs and Blood samples will be collected throughout study.

Trial Locations (2)

27157

RECRUITING

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

28204

RECRUITING

Levine Cancer Institute, Charlotte

All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

collaborator

Swim Across America

OTHER

lead

Wake Forest University Health Sciences

OTHER